EUVIMEDEUVIMED entdecken
Crossref

Outpatient Delivery of Step‐Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma

Aline G Ramírez-Alvarado, Ana Varela-Constantino, David Gómez-Almaguer iD, Roberto Ovilla-Martínez, Martha Alvarado-Ibarra, Fernando Pérez-Zincer, Christian Ramos-Peñafiel, Diego Cruz, Manuel Solano-Genesta, María Del Carmen López-Sánchez, Gilberto Israel Barranco-Lampon, Carolina García-Castillo und 1 weitere

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Aline G Ramírez-Alvarado und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unidad Médica de Alta Especialidad, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mex…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

New therapies are improving outcomes even in advanced stages of multiple myeloma.

Objectives

To describe the experience of bispecific antibodies (BsAbs) in Mexico.

Results

The study included 41 patients with triple‐class refractory (88%) and penta‐drug refractory (61%) myeloma. The median number of prior treatment lines was 3, and the median time to response was 2 months. Step‐up dosages were administered on an outpatient basis in 34 patients (83%). BsAbs were administered every 2 weeks to 19 patients (46%) and monthly to 17 patients (41.5%). Thirteen of these (31.5%) switched to monthly doses early in treatment and maintained their response. Twenty‐five of 38 evaluated patients (66%) achieved a complete response or better, and 84% were negative for minimal residual disease. The median response duration was 10 months, while median progression‐free survival and overall survival were 12 and 13 months, respectively. Extramedullary disease, no complete response, positivity for minimal residual disease, and penta‐refractoriness were associated with poor outcomes. The adverse events were lower than those reported in clinical trials.

Conclusions

In conclusion, using outpatient step‐up dosing followed by planned de‐escalation to monthly doses of BsAbs in responding patients with MM is feasible, safe, and effective, and may improve access to this novel therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificMultiple MyelomaAntineoplastic Agents, ImmunologicalHumansFemaleMaleAgedMiddle AgedTreatment OutcomeAdultDrug Administration ScheduleOutpatientsAged, 80 and over

Stichwörter der Autor:innen

bispecific antibodiesearly monthly dosingmyelomaoutpatient step‐uprefractory

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Unidad Médica de Alta Especialidad, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
  • Hospital Universitario de Nuevo León, Monterrey, Mexico.
  • Hospital Angeles Lomas, Mexico City, Mexico.
  • Hospital General de México, Secretaría de Salud, Mexico City, Mexico.
  • Instituto Oncológico del Noreste, Monterrey, Mexico.
  • ION Instituto Oncológico Nacional, Guadalajara, Mexico.

ORCID-Profile: David Gómez-Almaguer, Jorge Vela-Ojeda

Zitieren

APA

Ramírez-Alvarado, A. G., Varela-Constantino, A., Gómez-Almaguer, D., Ovilla-Martínez, R., Alvarado-Ibarra, M., Pérez-Zincer, F., Ramos-Peñafiel, C., Cruz, D., Solano-Genesta, M., Del Carmen López-Sánchez, M., Barranco-Lampon, G. I., García-Castillo, C., & Vela-Ojeda, J. (2026). Outpatient Delivery of Step‐Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma. European Journal of Haematology. https://doi.org/10.1111/ejh.70176

Vancouver

Ramírez-Alvarado AG, Varela-Constantino A, Gómez-Almaguer D, Ovilla-Martínez R, Alvarado-Ibarra M, Pérez-Zincer F, et al. Outpatient Delivery of Step‐Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma. European Journal of Haematology. 2026. doi:10.1111/ejh.70176

BibTeX
@article{RamrezAlvarado2026,
  author = {Ramírez-Alvarado, Aline G and Varela-Constantino, Ana and Gómez-Almaguer, David and Ovilla-Martínez, Roberto and Alvarado-Ibarra, Martha and Pérez-Zincer, Fernando and Ramos-Peñafiel, Christian and Cruz, Diego and Solano-Genesta, Manuel and Del Carmen López-Sánchez, María and Barranco-Lampon, Gilberto Israel and García-Castillo, Carolina and Vela-Ojeda, Jorge},
  title = {Outpatient Delivery of Step‐Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70176}
}
Kostenlos starten →